

Pixium Vision

Pixium cleared to start EU Prima feasibility study

Pixium has received clearance from the French regulatory agency (Agence Nationale de Sécurité du Médicament et des Produits de Santé, or ANSM) to start a feasibility study of its Prima sub-retinal bionic vision system (BVS) on up to five patients with advanced Dry-ARMD. It plans to complete the first implantation before YE17, and obtain six-month study data in H218. If results are positive, Pixium expects to start an EU pivotal study in H119. We have reinstated our Prima probability of success estimate in our model to 12.5% (from 10%), leading to an increase in our pipeline rNPV to €82.6m (from €63.0m, previously).

Year end	Revenue (€m)	PBT* (€m)	EPS* (€)	DPS (€)	P/E (x)	Yield (%)
12/15	3.3	(15.6)	(1.23)	0.0	N/A	N/A
12/16	2.5	(12.4)	(0.98)	0.0	N/A	N/A
12/17e	2.8	(13.3)	(1.01)	0.0	N/A	N/A
12/18e	3.0	(18.8)	(1.39)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Feasibility trial on patients with severe Dry-ARMD

The study will take place at Fondation Ophtalmologique Rothschild and Hôpital des Quinze-Vingt in Paris, and recruit up to five patients with advanced dry age-related macular degeneration (Dry-ARMD). Eligible patients will be required to have the most severe form of the disease, including a visual acuity (VA) of 20/400 or worse, with no light perception in the foveal (central portion of the retina) region, and an area of central retinal atrophy of at least 3-disc-diameters (approximately 5mm in length). If six-month results (expected H218) are positive, Pixium plans to start an EU pivotal study in early 2019. Pixium is currently also in discussions with the FDA and aims to obtain approval by YE17 to start a US feasibility study.

Dry-ARMD represents large opportunity for Prima

The prevalence of ARMD in adults above age 45 is estimated at 8.0%, and late stage Dry-ARMD (with best-corrected vision acuity of 20/200, or 10% or worse) affects about 0.4% of this age group. This represents about 815,000 people in Europe and 517,000 in the US. We continue to anticipate peak sales in Dry-ARMD of €722m in 2025.

Valuation: Risked-rNPV up to €73.4m

Our forecasts are unchanged but with the EU feasibility study now cleared, we reinstated our Prima probability of success estimate in our model to 12.5% (from 10%). We had previously lowered this probability to 10%, following the suspension of Iris II (due to its unexpectedly short lifespan). We now obtain a pipeline rNPV (enterprise value) of €82.6m, up from €63.0m, previously. After including €5.4m in net cash at H117 (€14.9m gross cash minus €1.4m in conditional advances and €8.1m in long-term debt), we obtain an equity valuation of €88.0m, or €6.58 per share (compared to €5.12, previously). We estimate that Pixium will raise €25m before YE18, €30m in 2019, and €40m in 2020. We have added these forecast funding requirements to long-term debt.

Prima to start EU study

Healthcare equipment & services

24 October 2017

Price €3.14

Market cap €42m

US\$1.18/€

Net cash (€m) at 30 June 2017 5.4

Shares in issue 13.4m


Free float 18%

Code PIX

Primary exchange Euronext Paris

Secondary exchange N/A

Share price performance



% 1m 3m 12m

Abs (41.6) (44.9) (46.3)

Rel (local) (42.7) (47.5) (55.1)

52-week high/low €7.3 €2.8

Business description

Pixium Vision is a French medical device company developing retinal implants for patients with retinitis pigmentosa and macular degeneration. CE Mark clearance was received in 2016 on its initial product, Iris II. A sub-retinal implant, Prima, is also being developed simultaneously.

Next events

Start Prima human feasibility study Q417

Start Prima EU pivotal study H119

Analysts

Pooya Hemami, CFA +1 646 653 7026

Maxim Jacobs, CFA +1 646 653 7027

healthcare@edisongroup.com

[Edison profile page](#)

Pixium Vision is a research client of Edison Investment Research Limited

Prima receives clearance to start EU feasibility study

Pixium announced on 19 October 2017 that it has received authorisation from the French regulatory agency, Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), to start a feasibility clinical study of its next-generation Prima wireless sub-retinal bionic vision system (BVS). The study will recruit up to five patients with advanced dry age-related macular degeneration (Dry-ARMD). To be eligible for the trial, patients will be required to have the most advanced forms of Dry-ARMD, thus requiring a visual acuity (VA) of 20/400 (5%) or worse, as well as no light perception in the foveal (central portion of the retina) region, and an area of central retinal atrophy of at least 3-disc-diameters (approximately 5mm in length).

Interim six-month data anticipated in H218

The Prima device is a micro photovoltaic chip of 2 millimetres in size, and equipped with 378 electrodes. The implant converts pulsed near infra-red invisible light signal received from the external glasses with an integrated mini-camera into electrical signals transmitted to the brain via the optic nerve. Compared to Pixium's Iris II epi-retinal BVS, Prima will be implanted under the retina (as opposed to on the surface of the retina) using a less invasive surgical procedure, which should be quicker and easier for surgeons to perform (the procedure is expected to be completed in under 90 minutes).

The current study will be conducted at Fondation Ophtalmologique Rothschild and Hôpital des Quinze-Vingt in Paris with vitreoretinal surgeon Dr Yannick Le Mer acting as the principal investigator performing the implantations. Patients will be evaluated for safety and efficacy measures (including ability to elicit light-perception and VA) for 36 months, but interim data will be available at 6, 12, 18 and 24 months as well. Pixium anticipates completing the first implantation before YE17 and potentially complete recruitment by mid-2018. If six-month data (anticipated H218) is positive (showing some signs of visual perception or improved VA), Pixium plans to start an EU pivotal trial in early 2019 (consistent with our existing forecasts). With the EU clinical strategy now underway, the firm reiterates that it is pursuing discussions in parallel with the FDA to obtain approval to start a US feasibility study. Pixium believes it could receive US Investigational Device Exemption (IDE) approval by YE17, and a US study could potentially begin in Q118.

Potentially better vision than Iris II

Prima could potentially provide better visual resolution than Iris II, as instead of directly stimulating retinal ganglion cells (RGCs, located more downstream in the visual signal processing) as Iris II does, Prima aims to stimulate bipolar cells (more mid-stream in physiological visual signal processing). In normal visual function, photoreceptor cells (located on the outer portion of the retina, or closer to the choroid) send information to bipolar cells (located within the retina), which then relay information into RGCs (which are on the inner portion of the retina). Because Prima functions more upstream, it allows for more physiological or natural image signal processing. Directly stimulating bipolar cells (as opposed to RGCs) involves lower electrical stimulation thresholds (to elicit a perceptual response), since the functioning inner retinal cells amplify the raw electrical signals before sending them to the optic nerve. The reduced energy requirement allows Prima to operate through a wireless approach, through micro photodiodes, thus eliminating the need for permanent trans-scleral wires (as needed by Iris II). Given its wireless mode of operation and lack of need for trans-scleral wiring, we do not expect the durability issues that have affected Iris II are likely to occur with Prima.

In addition, Prima uses a higher electrode count than Iris II (378 versus 150), which also supports the potential attainment of higher VA. Animal studies suggest Prima could reach up to 20/250 in

humans (reflecting 8% of the resolution seen by healthy individuals). If replicated in humans, this could be sufficient to provide meaningful improvements and justify implantations in patients in late stages of the Dry-ARMD, such as those with geographic retinal atrophy reducing best-corrected VA in both eyes to below 20/200. This leads to much wider potential clinical use than the retinitis pigmentosa (RP) or retinal dystrophy markets targeted for Iris II. The prevalence of ARMD in adults above age 45 is estimated at 8.0%, and late-stage ARMD (with best-corrected vision acuity of 20/200, or 10% or worse) affects about 0.4% of this age group.¹ This represents about 815,000 people in Europe and 517,000 in the US.

Valuation and financials

The attainment of regulatory clearance to start the Prima study is a de-risking step. Pixium had originally guided in H216 that it had expected this milestone to occur by YE16, but French regulators then requested additional data, causing some uncertainty to the timing of this event. With clearance now secured, Pixium can concentrate on starting first-in human implantations. Our Prima development and commercialisation timelines (potential EU launch in 2021) and sales forecasts are unchanged (please refer to our [5 October 2017 update note](#) for further details). With the EU feasibility study about to start, we have raised our Prima probability of success estimate in our model from 10% to 12.5%.

Exhibit 1: Pixium Vision rNPV assumptions							
Product contributions (net of R&D and marketing costs)	Indication	Status	rNPV (€m)	rNPV/share (€)	Probability of success	Launch year	Peak WW sales (€m)
Iris-II	Retinitis pigmentosa	CE mark but sales suspended	17.3	1.30	40.0%	Relaunch in 2019	48 in 2022
Prima	Retinitis pigmentosa	Preclinical	31.0	2.32	12.5%	2021 (EU) and H222 (US)	185 in 2025
Prima	Age-related macular degeneration	Preclinical	125.5	9.39	12.5%	2021 (EU) and H222 (US)	722 in 2025
Corporate costs & expenses							
G&A expenses			(28.4)	(2.12)			
Net capex, NWC & taxes			(62.9)	(4.70)			
Total rNPV			82.6	6.18			
Net cash (debt) (H117)			5.4	0.41			
Total equity value			88.0	6.58			
FD shares outstanding (000) (H117)			13,365				

Source: Edison Investment Research

Given the above changes, we now obtain a pipeline rNPV (enterprise value) of €82.6m, up from €63.0m, previously. After including €5.4m in net cash at H117 (€14.9m gross cash minus €1.4m in conditional advances and €8.1m in long-term debt), we obtain an equity valuation of €88.0m, or €6.58 per share (compared to €5.12, previously).

Financials

We continue to assume 2017 and 2018 operating cash burn rates (excluding net interest) of €13.4m and €13.6m, respectively. While we believe Pixium has enough gross cash to maintain operations into H118, we expect it will draw the last remaining €3m tranche from the €11m Kreos financing facility in H217 to strengthen its runway and augment financial flexibility. For the same reason, we also continue to assume that Pixium will raise an additional €10m in H217 and €15m in 2018. Our model assumes that, strictly speaking, Pixium would only require €10m in funding to maintain a positive cash balance at YE18, but to maintain operational flexibility and avoid the need

¹ Wong WL, Su X, Li X et al. Lancet Glob Health. 2014 Feb;2(2):e106-16.

to pursue funding methods of last resort, we assume, as is the case for most of our coverage universe, that the firm will seek to always maintain at least six months of financial runway in terms of cash and equivalents on-hand. Hence, our model continues to assume the firm will raise €25m in total, through YE18, in funding beyond the Kreos financing facility.

For illustrative purposes only, we have added our forecast funding requirements to long-term debt. However, it is possible that Pixium may be required to raise equity instead of debt, to meet its funding needs. The company announced on 23 October 2017 that it entered into an equity line of credit with Kepler Chevreux, who has provided a firm commitment to purchase 2m common shares of Pixium (reflecting, at current pricing, c €6.2m in funding after discounts) within two years. The shares will be issued based on the lowest of the daily volume-weighted average price of the two trading days preceding each issuance, minus a discount of up to 7.5%. Pixium has the option to suspend or terminate this agreement at any time.

We continue to estimate that Pixium will raise €30m in 2019, and €40m in 2020. As above, we have added these forecast funding requirements to long-term debt. We forecast that this funding should enable the completion of registration-enabling Prima clinical studies in both the EU and the US, to meet our estimated launch timelines. This timing for these projected funding requirements can be delayed to a certain extent, should the firm plan to complete US Prima pivotal studies over a longer-time horizon than we currently anticipate (ie thus leading to a potential US launch in or after 2023). Our financial and valuation models do not include the potential dilutive effects of future equity offerings. We continue to assume that Pixium will only start to become cash flow positive on a sustainable basis once Prima is launched (in 2021).

Exhibit 2: Financial summary

	€(000)	2015	2016	2017e	2018e	2019e
31-December		IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS						
Revenue		3,296	2,516	2,755	3,000	3,496
Cost of Sales		0	(141)	(562)	0	(2,439)
General & Administrative		(2,680)	(2,953)	(4,213)	(3,578)	(8,168)
Research & Development		(15,169)	(10,869)	(9,491)	(14,000)	(18,000)
EBITDA		(14,552)	(11,448)	(11,510)	(14,578)	(25,110)
Depreciation		(1,144)	(1,051)	(1,006)	(1,133)	(2,712)
Amortisation		0	0	0	0	0
Operating Profit (before exceptionals)		(15,697)	(12,499)	(12,516)	(15,711)	(27,822)
Exceptionals		0	0	0	0	0
Other		0	0	0	0	0
Operating Profit		(15,697)	(12,499)	(12,516)	(15,711)	(27,822)
Net Interest		52	58	(813)	(3,099)	(5,720)
Profit Before Tax (norm)		(15,644)	(12,441)	(13,329)	(18,810)	(33,541)
Profit Before Tax (FRS 3)		(15,644)	(12,441)	(13,329)	(18,810)	(33,541)
Tax		0	0	0	0	0
Profit After Tax and minority interests (norm)		(15,644)	(12,441)	(13,329)	(18,810)	(33,541)
Profit After Tax and minority interests (FRS 3)		(15,644)	(12,441)	(13,329)	(18,810)	(33,541)
Average Number of Shares Outstanding (m)		12.7	12.7	13.2	13.6	13.8
EPS - normalised (€)		(1.23)	(0.98)	(1.01)	(1.39)	(2.42)
EPS - normalised and fully diluted (€)		(1.23)	(0.98)	(1.01)	(1.39)	(2.42)
EPS - (IFRS) (€)		(1.23)	(0.98)	(1.01)	(1.39)	(2.42)
Dividend per share (€)		0.0	0.0	0.0	0.0	0.0
BALANCE SHEET						
Fixed Assets		11,087	10,184	9,563	12,430	16,718
Intangible Assets		8,822	8,205	7,942	7,942	7,942
Tangible Assets		2,265	1,979	1,621	4,488	8,776
Current Assets		27,682	17,405	24,671	18,803	11,992
Short-term investments		0	0	0	0	0
Cash		24,354	14,244	20,740	14,995	7,332
Other		3,328	3,161	3,931	3,808	4,659
Current Liabilities		(3,498)	(2,836)	(880)	(880)	(1,074)
Creditors		(3,498)	(2,836)	(880)	(880)	(1,074)
Short term borrowings		0	0	0	0	0
Long Term Liabilities		(315)	(1,505)	(22,678)	(37,678)	(67,678)
Long term borrowings		(164)	(1,333)	(22,490)	(37,490)	(67,490)
Other long term liabilities		(151)	(172)	(187)	(187)	(187)
Net Assets		34,956	23,248	10,676	(7,325)	(40,041)
CASH FLOW						
Operating Cash Flow		(15,584)	(11,188)	(13,425)	(13,646)	(24,943)
Net Interest		52	58	(813)	(3,099)	(5,720)
Tax		0	0	0	0	0
Capex		(2,106)	(148)	(176)	(4,000)	(7,000)
Acquisitions/disposals		0	0	0	0	0
Financing		56	(0)	(38)	0	0
Net Cash Flow		(17,582)	(11,279)	(14,452)	(20,745)	(37,662)
Opening net debt/(cash)		(41,965)	(24,190)	(12,911)	1,751	22,495
HP finance leases initiated		0	0	0	0	0
Other		(193)	(0)	(209)	0	0
Closing net debt/(cash)		(24,190)	(12,911)	1,751	22,495	60,158

Source: Edison Investment Research, Pixium Vision accounts. Note: 2015 and 2016 revenues include tax credits and subsidies, which are forecast at approximately \$3m per year through 2018.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Pixium Vision and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.